跳至主要内容
临床试验/NL-OMON54721
NL-OMON54721招募中4 期

Safety of TKI concurrent with cranial radiotherapy in NSCLC patients; the SATIN platform trial - SATI

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • To be eligible to participate in this study, a patient must meet all of the
  • following criteria:
  • - Stage IV NSCLC with driver mutation, treated with TKI, development of brain
  • metastases during TKI treatment
  • - Indication for cranial radiotherapy determined by treating physician and
  • radiation oncologist
  • - Age >= 18 years
  • - Ability to understand neurocognitive testing
  • - Written informed consent

排除标准

  • A potential patient who meets any of the following criteria will be excluded
  • from participation in this study:
  • - Prior radiotherapy to the brain when this precludes new radiotherapy.
  • - Neurologic/psychiatric illnesses (such as Alzheimer*s disease)
  • - Claustrophobia
  • - Metal implants or other contra-indication for MRI
  • - Inability to lie supine for 30 minutes time (MRI)

研究者

发起方
Medisch Universitair Ziekenhuis Maastricht

相似试验